TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Single Dose Corticosteroids on Response to Allergens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is allergic to Timothy grass pollen~* Female patients have a negative pregnancy test and agree to use birth control throughout the study~* Male patients agree to use birth control throughout the study~* Patient has been a nonsmoker for at least 6 months~* Patient agrees to avoid the use of aspirin and other Non-steroidal anti-inflammatory drugs (NSAIDs) throughout study~Exclusion Criteria:~* Patient is breastfeeding~* Patient has any respiratory disease other than mild stable asthma that does not require treatment~* Patient consumes more than 3 alcoholic beverages per day~* Patient consumes more than 6 caffeinated beverages per day~* Patient has had major surgery or has donated or lost 1 unit of blood within 4 weeks of screening~* Patient has severe allergies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): placebo
- B (Type: ACTIVE_COMPARATOR): 10 mg prednisone
- C (Type: ACTIVE_COMPARATOR): 25 mg prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Tiotropium Add-on Therapy in Patients With Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with least one asthma diagnosis in the inpatient setting or at least two separate instances of asthma diagnosis (separated by at least 30 days) recorded in the outpatient or emergency room setting will be included.~* Patients will be required to be already on Inhaled Corticosteroid/Long-acting beta-agonist (ICS/LABA).~* Patients will be required to have available records 12 months prior to the index date.~Exclusion Criteria:~* Patients below the age of 6 years on the Inhaled Corticosteroid/Long-acting beta-agonist initiation (ICS/LABAi) date will be excluded.~* Patients with a diagnosis of COPD at any time during the study period will be excluded.~* Those who are on biologics at baseline will be removed.~* After the PSM process, unmatched patients will be excluded.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Asthma (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Dose of Omeprazole After Endoscopic Treatment of Bleeding Peptic Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Above 21 year old~2. OGD done within 48 hrs of admission~3. No recent upper GIT surgery past one month~4. Forrest Type I, IIa \& IIb ulcer (Type Ia: Spurting, Ib:Oozing, IIa: Visible vessel, IIb: Clot)~5. Non-malignant ulcer~6. Informed consent taken~Exclusion Criteria:~1. Impaired hepatic function~2. Pregnancy~3. Lactation~4. Concomitant medication (warfarin, diazepam, phenytoin, chlarithromycin, cimetidine and digoxin)~5. Underlying malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): regular dose versus high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients of the age of 2 years and older suffering from a tree pollen induced seasonal allergic rhinitis~Exclusion Criteria:~* Patients suffering from acute or chronic infections or inflammations~* Patients suffering from secondary modifications of the target organ with function impairment (emphysema, bronchiectasis)~* Patients suffering from severe and uncontrolled asthma~* Patients with a known severe autoimmune disease~* Patients with active malignant disease~* Patients requiring beta-blockers~* Patients having any contraindication for the use of adrenaline~* Patients with a hypersensitivity to the excipients of the drug

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ORALVAC COMPACT BÄUME (Type: None): This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Osteopathic Otitis Media Research Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 months up to second birthday~* Documented presence of acute otitis media following the 2004 AAP/AAFP Guidelines within 3 days of entry into the study~Exclusion Criteria:~* Chromosomal abnormalities~* Major congenital malformations of the head and neck, including torticollis~* Immunologic abnormalities or deficiencies~* Any prior ear-nose-throat surgery performed as a treatment for otitis media~* Any tube placement surgery scheduled during the four weeks of the study.~* Normal tympanograms at entry into study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- Standard Care Plus OMM (Type: EXPERIMENTAL): Subjects will receive active intervention with osteopathic manipulative medicine (OMM) using a prescribed standardized treatment protocol which is age appropriate. Subjects will also receive standard care for otitis media from their referring physician.
- Standard Care Only (Type: NO_INTERVENTION): Subjects will receive standard care only for otitis media from their regular referring physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma).~Exclusion Criteria:~* Patients not administered Torisel.~* Patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: None): Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Medical Student Use of Templates to Document Outpatient Asthma Care in Electronic Medical Record

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Third year medical student completing family medicine clerkship Uniformed Services University~Exclusion Criteria:~* All students other than those listed above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention group (Type: EXPERIMENTAL): None
- Control Group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and 12 years of age and older and weigh at least 40 kg~2. Diagnosed with severe hemophilia A (baseline Factor VIII level less than 1%)~3. History of at least 100 exposure days to any Factor VIII product~Exclusion Criteria:~1. History of Factor VIII inhibitors~2. Kidney or liver dysfunction~3. Diagnosed with another coagulation defect other than hemophilia A

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
- B (Type: EXPERIMENTAL): Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in NN7999-3747 (NCT01333111) and/or NN7999-3773~Exclusion Criteria:~* Known history of FIX inhibitors based on existing medical records, laboratory report reviews and patient and LAR (legal acceptable representative) interviews~* Current FIX inhibitors above or equal to 0.6 BU (Bethesda Units)~* Congenital or acquired coagulation disorders other than haemophilia B~* Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)~* Any disease (liver, kidney, inflammatory and mental disorders included) or condition which, according to the Investigator's (trial physician) judgement, could imply a potential hazard to the patient, interfere with trial participation, or interfere with trial outcome

- Gender: MALE
- Minimum Age: 13 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis, high dose (once weekly) (Type: EXPERIMENTAL): None
- Prophylaxis, low dose (once weekly) (Type: EXPERIMENTAL): None
- On-demand (Type: EXPERIMENTAL): None
- Prophylaxis, high dose (every second week) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
1. 18 years of age or older; male or female.~2. Able to provide written informed consent.~3. Must be scheduled for elective unilateral total hip replacement surgery. Only primary surgeries accepted.~4. If female, must be either one year post-menopausal, surgically sterile, or using medically accepted contraceptive measures as judged by the Investigator and in accordance with local regulatory requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence~* Body tumor 1-6, the maximum tumor length \< 5 cm~* KPS ≥ 70, lifespan \> 6 months~* Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L~Exclusion Criteria:~* Patients with cardiac pacemaker~* Patients with brain metastasis~* Patients withgrade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cryosurgery and NK immunotherapy (Type: EXPERIMENTAL): In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
- Cryosurgery (Type: ACTIVE_COMPARATOR): In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) Framingham risk score of 10% or less~* Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L) and \<190 mg/dL~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* History of coronary heart disease~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Diabetes mellitus (Type 1 diabetes, poorly controlled type 2 diabetes)~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
- Placebo QM (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
- Ezetimibe (Q2W) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
- Ezetimibe (QM) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
- Evolocumab Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
- Evolocumab QM (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Connectivity-based rTMS and State-Dependency on Amygdala Activation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age Restrictions: Young Group (from 18 to 35 years old)~* Use of effective method of birth control for women of childbearing capacity.~* Willing to provide informed consent.~Exclusion Criteria:~* Current or recent (within the past 6 months) history of substance abuse or dependence.~* Current serious medical illness.~* History of seizure, epilepsy, stroke, brain surgery, head injury, cranial metal implants, known structural brain lesion, devices that may be affected by rTMS or MRI (pacemaker, medication pump, cochlear implant, implanted brain stimulator)~* Inability or unwilling to give informed consent.~* Diagnosed any Axis I DSM-IV disorder (MINI, DSM-IV).~* Clinically defined neurological disorder.~* Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or currently taking medication that lowers the seizure threshold.~* Claustrophobia (MRI scanner).~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Repetitive TMS (rTMS) (Type: ACTIVE_COMPARATOR): excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)
- Sham repetitive TMS (rTMS) (Type: SHAM_COMPARATOR): electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Exclusion Criteria:~1. Known pregnancy~2. Prisoner

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy volunteers (iterative device development) (Type: OTHER): This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Volunteers will be randomized to receive alternating 5 minute episodes of various vibration frequencies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females greater than 65 years of age~2. Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 150 mmHg but less than 200 mm Hg and a mean seated diastolic blood pressure (MSDBP) less than or equal to 109 mmHg following a 2-3 week single blind placebo run-in period.~3. The difference in MSSBP between visits 2 and 3 or between visits 3 and 3x must be less than or equal to 10 mmHg.~4. Patients with a mean daytime (8am-4pm) systolic blood pressure (SBP) greater than or equal to 140 mmHg and less than or equal to 199 mmHg and a mean daytime diastolic blood pressure (DBP) less than or equal to 109 mmHg as measured by an ambulatory blood pressure monitoring device (ABPM) following placebo run-in period.~Exclusion Criteria:~1. History of stroke or transient ischemic attack (TIA) within the last one year.~2. History of myocardial infarction, angina, coronary angioplasty, coronary artery bypass graft, or heart failure within the past 6 months.~3. Severe hypertension (diastolic blood pressure greater than 115 mmHg or systolic blood pressure greater than or equal to 200 mmHg).~4. Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma or Cushing's syndrome.~5. Type I diabetes or Type II diabetics not on stable treatment for greater than or equal to 4 weeks and plasma glucose greater than 160 mg/dl.~6. Evidence of symptomatic resting bradycardia, congestive heart failure, or hemodynamically significant cardiac valvular disease.~7. Presence of heart block greater than first degree sinoatrial block, Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, an accessory bypass tract, atrial fibrillation, atrial flutter or any arrhythmia requiring medication.~8. Serum Creatinine greater than 1.7 mg/dl, or other abnormal laboratory values deemed clinically significant by the investigator.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete